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Abstract
Background: To characterize the sequential events that are taking place in retinal neurodegeneration in a murine model of
spontaneous type 2 diabetes (db/db mouse).
Methods: C57BLKsJ-db/db mice were used as spontaneous type 2 diabetic animal model, and C57BLKsJ-db/+ mice served
as the control group. To assess the chronological sequence of the abnormalities the analysis was performed at different
ages (8, 16 and 24 weeks). The retinas were evaluated in terms of morphological and functional abnormalities
[electroretinography (ERG)]. Histological markers of neurodegeneration (glial activation and apoptosis) were evaluated by
immunohistochemistry. In addition glutamate levels and glutamate/aspartate transporter (GLAST) expression were
assessed. Furthermore, to define gene expression changes associated with early diabetic retinopathy a transcriptome
analyses was performed at 8 week. Furthermore, an additional interventional study to lower blood glucose levels was
performed.
Results: Glial activation was higher in diabetic than in non diabetic mice in all the stages (p,0.01). In addition, a progressive
loss of ganglion cells and a significant reduction of neuroretinal thickness were also observed in diabetic mice. All these
histological hallmarks of neurodegeneration were less pronounced at week 8 than at week 16 and 24. Significant ERG
abnormalities were present in diabetic mice at weeks 16 and 24 but not at week 8. Moreover, we observed a progressive
accumulation of glutamate in diabetic mice associated with an early downregulation of GLAST. Morphological and ERG
abnormalities were abrogated by lowering blood glucose levels. Finally, a dysregulation of several genes related to
neurotransmission and oxidative stress such as UCP2 were found at week 8.
Conclusions: Our results suggest that db/db mouse reproduce the features of the neurodegenerative process that occurs in
the human diabetic eye. Therefore, it seems an appropriate model for investigating the underlying mechanisms of diabetes-
induced retinal neurodegeneration and for testing neuroprotective drugs.
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Introduction
Diabetic retinopathy (DR) is the most common complication of
diabetes and one of the leading causes of preventable blindness [1].
Current treatments for DR are applicable only at advanced stages
of the disease and are associated with significant adverse effects
[2,3]. Therefore, new pharmacological treatments for the early
stages of the disease are needed. However, the mechanisms
involved in the onset of DR are still poorly understood.
Emerging evidence suggests that retinal neurodegeneration is an
early event in the pathogenesis of DR [4–8] which participates in
the microcirculatory abnormalities that occur in DR [9–13].
Consequently, new therapeutic strategies based on neuroprotec-
tion have been proposed [14–15].
The experimental model currently used to study retinal
neurodegeneration in DR is the rat with streptozotocin-induced
diabetes (STZ-DM). However, since STZ is neurotoxic itself [16],
a debate has arisen regarding the appropriateness of this model for
examining retinal neurodegeneration shortly after STZ adminis-
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tration. A second rodent model, the Ins2Akita (Akita) mouse,
which contains a dominant point mutation in the gene encoding
for insulin-2 that induces spontaneous type 1 diabetes in the B6
mouse strain, reproduces some findings of the neurodegenerative
process that occurs in the human diabetic retina [17]. However,
both STZ-DM and Akita mouse are models of type 1 diabetes and
further characterization of the neurodegenerative process in type 2
models is needed.
In recent years the C57BL/KsJ-db/db mouse has been used as a
spontaneous diabetic model of type 2 diabetes to investigate the
pathogenesis of DR [17–23]. The C57BL/KsJ-db/db mouse
carries a mutation in the leptin receptor gene and is a well-
established model of obesity-induced type 2 diabetes. Several
authors have reported the presence of retinal neurodegeneration
(apoptosis, glial activation and retinal thinning) in this model
[19,22]. Therefore, C57BL/KsJ-db/db seems appropriate for
investigating the underlying mechanisms of retinal neurodegener-
ation associated with diabetes and for testing new drugs. However,
the characterization of the retinal neurodegenerative process and
its functional consequences in db/db mice is far from being
completed. In addition, whether neurodegeneration can be
attributed to genetic factors rather than to diabetes is a question
which remains to be elucidated.
In the present study we have characterized the neurodegener-
ative process that occurs in the retina of C57BL/KsJ-db/db mice
by examining morphological, biochemical and functional abnor-
malities in a sequential manner (8, 16, 24 weeks). Moreover, a
transcriptomic analysis in 8-week old diabetic mice was performed
to identify new potential causative candidates of DR. In addition,
we have demonstrated that the neurodegenerative process is
significantly arrested after blood glucose levels have been lowered.
Overall, our results suggest that C57BL/KsJ-db/db reproduces the
neurodegenerative features that occur in the human diabetic eye,
and is an appropriate experimental model for studying the




A total of 90 C57BL/KsJ-db/db male mice obtained from
Harlan Laboratories, Inc. were divided into two groups: 45 non-
diabetic (db/+) and 45 diabetic mice (db/db). To assess the
chronological sequence of the retinal abnormalities associated with
diabetes, 15 diabetic mice (db/db) were compared with 15 age-
matched non-diabetic mice (db/+) at different ages (8, 16 and 24
weeks). Blood glucose concentrations were measured from the tail
vein (glucose assay kit; Abbott). Mice were housed under
controlled conditions of temperature (20uC) and humidity (60%)
with a 12-hour light/dark cycle and had free access to food and
water.
Interventional study. Diabetic mice (db/db) 8 weeks old
received diet ad libitum (n = 10) or restrictive diet (normal chow
diet restricted to 60% of total daily calories; n = 10) for 15 days.
Ten non-diabetic mice matched by age served as control group. At
day 15 the animals were euthanized by cervical dislocation and the
eyes enucleated.
This study was approved by the Animal Care and Use
Committee of VHIR (Vall d’Hebron Research Institute). All the
experiments were performed in accordance with the tenets of the
European Community (86/609/CEE) and ARVO (Association for
Research in Vision and Ophthalmology).
Electroretinography
Before retinal electrophysiological tests, the animals were dark-
adapted (12 hours overnight) and anesthetized under a dim red
light with a 2% isoflurane/O2 mixture. Pupils were dilated with
topic 1% tropicamide and ciclopegic was applied on the corneal
surface. Full field electroretinography (ERG) recordings were
measured using an HMsERG (Ocuscience) with two recording
channels. Recordings were measured from corneal electrodes
attached to the corneas by a lens embedded in 1% methylcellulose
to avoid cornea dehydratation. Two needle probes were inserted
for reference subcutaneously between each jaw and a grounding
probe were inserted into the base of the tail. Then their noses were
inserted into a mini Ganzfeld flash photo-stimulator with white
LED.
Scotopic ERG stimuli were simultaneously recorded from both
eyes of dark-adapted (12–16 hours) mice. Light stimuli were
delivered via a Ganzfeld light source with flash intensities from 30
to 30000 mcd.s/m22. Responses were amplified 5000X, high-pass
filtered with a 10-Hz cutoff frequency, and low-pass filtered at
300 Hz using an amplifier. The ERG voltage and stimulus-
monitor signals were digitalized with hardware (HMsERG) and
software (HMsERG View) from Ocuscience. Data were recorded
at either 0.2 or 0.5 ms/pt. A stimulus set consisted of 3 to 20
responses at the same wavelength and intensity of light. The
oscillatory potentials (OPs) were isolated by a band-pass filtering
the retinal response between 34 and 300 Hz. We chose 34 Hz as a
cutoff frequency to avoid any loss of signal power, especially for
the slower OPs of diabetic animals. OPs were isolated for a light
stimulus of 3000 mcd.s/m22.
The amplitude and implicit time of the ERG a-and b-waves
were measured at the maximum negative and positive peaks of the
recordings with respect to the baseline before stimulation. As
recommended by the ISCEV (International Society for Clinical
Electrophysiology of Vision) [24] OP amplitudes were measured
from the negative peak to the next positive peak whereas OP
latencies were measured at the positive peaks. We added up OP
amplitudes (SOP amplitude) and implicit time (SOP implicit time)
for the first 5 OPs.
Tissue Processing
Mice were euthanized by cervical dislocation. The eyes were
immediately enucleated and the neuroretina was separated. The
neuroretina from one of the eyes was frozen in liquid nitrogen and
Figure 1. Blood glucose levels (black marks) and body weight
(white marks) in db/+ (circles; n = 12) and db/db mice (triangles;
n = 12). Values are expressed as mean 6 SD. *p,0.05; **p,0.001.
doi:10.1371/journal.pone.0097302.g001
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Figure 2. b-wave implicite time (ms) in non diabetic and diabetic mice at 8 (A), 16 (C) and 24 weeks (E). SOPs implicit time (ms) (G). b-wave
amplitude (mV) in non diabetic and diabetic mice at 8 (B), 16 (D) and 24 weeks (F). SOPs amplitude (mV) (H). White bars: non diabetic mice. Black bars:
diabetic mice. Data are expressed as mean 6 SD. *p,0.05; **p,0.01;***p,0.001.
doi:10.1371/journal.pone.0097302.g002
Figure 3. a-wave implicit time (ms) in non diabetic and diabetic mice at 8 (A), 16 (C) and 24 weeks (E). a-wave amplitude (mV) in non diabetic and
diabetic mice at 8 (B), 16 (D) and 24 weeks (F). White bars: non diabetic mice. Black bars: diabetic mice. Data are expressed as mean 6 SD. *p,0.05.
doi:10.1371/journal.pone.0097302.g003
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stored at –80uC for protein assessments. The other eye was flash
frozen in Tissue Freezing Medium (TFM, Electron Microscopy
Sciences), by immersion in liquid nitrogen, and cryosectioned at
8 mm through the dorsal/ventral plane. Sections were mounted on
slides and stored at 280uC. These sections were prepared for the
assessment of retinal morphology, evaluation of GFAP and
TUNEL immunoreactivity. For caspase-3 immunohistochemistry,
the eyes were fixed overnight in 10% neutral buffered formalin
and embedded in paraffin. Ocular globes embedded in paraffin
were sectioned (3 mm) along the eye axis.
Neurodegeneration Measurements
Retinal morphometry. Microscopic evaluation of retinas
included scanning tissue sections to evaluate morphology followed
by systematic morphometric analysis. The sections were stained
with hematoxylin and eosin (H&E). Images of H&E sections were
captured with a microscope (Olympus, Lake Success, NY) using
the program Image J for quantification. The measurements were
taken at two peripheral and three central regions of the retina and
were examined to ensure similar locations of measurements for all
eyes. Sections through the posterior eye segment were defined as
central retina when the plane passed through the optic nerve or at
less than 300 mm from the optic head rim. The remaining sections
from both sites of the optic nerve were considered as peripheral
Figure 4. Thickness of total retina (A), outer nuclear layer (B) and inner nuclear layer (C). The measurements have been performed in the
central retina and in peripheral retina. Results are expressed as mean 6 SD. *p,0.05 between non diabetic (white bars) and diabetic (black bars)
mice.
doi:10.1371/journal.pone.0097302.g004
Figure 5. Images demonstrating the progressive loss of cells in retinal ganglion layer (GCL). A) Hematoxylin and eosin stained central
retina in a representative case of a diabetic mouse (upper panel) and a non-diabetic mouse (lower panel) of 8, 16 and 24 weeks old. In the diabetic
retina a loss of cells in GCL was observed. B) Cell number in GCL in control and diabetic mice in central retina. C) Comparison of TUNEL
immunofluorescence (green) between representative samples from a diabetic (upper panel) and a non-diabetic mouse (lower panel) at 8 weeks, 16
and 24 weeks. Nuclei were labeled with Hoechst (blue). D) Percentage of TUNEL positive cells in the GCL in non-diabetic and diabetic mice at 8, 16
and 24 weeks (upper panel). ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell
layer. Results are expressed as mean 6 SD. White bars: non-diabetic mice; Black bars: diabetic mice. *p,0.05, **p,0.001 between non-diabetic and
diabetic mice.
doi:10.1371/journal.pone.0097302.g005
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retina. Image analysis of ten sections of each region were used to
quantify total retinal thickness, the thickness of the inner nuclear
layer (INL), outer nuclear layer (ONL) and cell number per mm2
in ganglion cell layer (GCL). These measurements were performed
by two of the investigators (P.B and L.C).
Immunohistochemical analysis for glial activation
assessment. Glial activation was evaluated by fluorescence
Figure 6. Comparison of cleaved caspase-3 immunofluorescence (green) between representative samples from a diabetic (upper
panel) and a non-diabetic mouse (lower panel) at 8, 16 and 24 weeks. Insets show the increased expression of cleaved caspase-3 in cells
residing in the ganglion cell layer (GCL) in db/db mice. Nuclei counterstained with Hoescht (blue). ONL: outer nuclear layer; INL: inner nuclear layer; C-
: negative control; C+: positive control mouse jejunal villi. Scale bars: 40 mm.
doi:10.1371/journal.pone.0097302.g006
Figure 7. Transmission electron micrographs of photoreceptors in a representative case of a non-diabetic (left panel) and a diabetic
mouse (right panel) 8 weeks old. Arrows indicate nuclear fragmentation. Scale bars: 6.71 mm.
doi:10.1371/journal.pone.0097302.g007
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microscopy using specific antibodies against GFAP (Glial fibrillar
acidic protein). Sections were fixed in acid methanol (220uC) for
2 min, followed by three washes with PBS, 5 min each. Sections
were permeabilized with TBS-Triton X-100 0,025% and were
incubated in blocker (1% BSA, and 10% goat serum in PBS) for 2
hours at room temperature. Sections were then incubated with
rabbit anti- GFAP (Abcam Ltd, Cambridge, U.K.) (1:500 dilution
prepared in blocking solution) overnight at 4uC in a humid
atmosphere. After three washes in PBS, 5 min each, the sections
were incubated with secondary antibody Alexa 488 goat-anti-
rabbit (Life Technologies S.A, Madrid, Spain) (1:200 dilution
prepared in blocking solution). The sections were washed three
times in PBS, counterstained with Hoesch and mounted with
Mounting Medium Fluorescence (Prolong, Invitrogen) and
mounted with a coverslip. Comparative digital images from
diabetic and control samples were recorded with an Olympus
microscope using identical brightness and contrast settings.
To evaluate the degree of glial activation we used a scoring
system based on extent of GFAP staining previously used [25].
The scoring system was as follows: Mu¨ller cell endfeet region/
GCL only (score 1); Mu¨ller cell endfeet region/GCL plus a few
proximal processes (score 2); Mu¨ller cell endfeet plus many
processes, but not extending to ONL (score 3); Mu¨ller cell endfeet
plus processes throughout with some in the ONL (score 4); Mu¨ller
cell endfeet plus lots of dark processes from GCL to outer margin
of ONL (score 5).
Figure 8. Glial activation. A) Comparison of GFAP immunofluorescence (green) between representative samples from a diabetic (upper panel) and
a non-diabetic mouse (lower panel) at 8 weeks, 16 and 24 weeks. In the diabetic retina, the Mu¨ller cells’ endfeet show abundant GFAP
immunofluorescence and the radial processes stain intensely throughout both the inner and outer retina. Nuclei were labeled with DAPI (blue). ONL:
outer nuclear layer; INL: inner nuclear layer; GCL: ganglion cell layer. B) Quantification of glial activation based on extent of GFAP staining.
doi:10.1371/journal.pone.0097302.g008
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Immunohistochemical analysis for apoptosis
assessment. Apoptosis was evaluated using the TUNEL
(Terminal Transferase dUTP Nick-End Labeling) method coupled
with fluorescein (DeadEnd Fluorometric TUNEL System kit;
PROMEGA, USA) with Hoechst 33342, Trihydrochloride,
Trihydrate (Molecular Probes) staining. Cryosections of retina
were permeabilised by incubation for 2 min on ice with 0.1%
Triton X-100 in 0.1% sodium citrate, freshly prepared. Apoptotic
cells were identified using green fluorescence [Alexa Fluor 594
goat-anti-rabbit (Invitrogen) (1:200 dilution prepared in blocking
solution with 5% BSA)]. For evaluation by fluorescence micros-
copy an excitation wavelength in the range of 450–500 nm (e.g.,
488 nm) and detection in the range of 515–565 nm (green) was
used.
Immunohistochemistry for caspase-3. Paraffined sections
were rehydrated and washed in 0.01-M phosphate buffered saline
(PBS). Then, they were incubated over night at 4uC with a rabbit
anti-cleaved caspase-3 antibody (Cell Signalling Technology, Inc.,
Danvers, USA) at 1:300 dilution. Then, ocular sections were
washed in PBS and incubated with the specific secondary antibody
biotinylated anti-rabbit IgG (1:100) (Vector Laboratories, Burlin-
game, USA). Once washed in PBS, a streptavidin Alexa Fluor 488
conjugate (Molecular Probes-Life Technologies, Grand Island,
USA) at 1:100 dilution was used to detect cleaved caspase-3
immunolabelling; the incubation was made over night at 4uC.
Figure 9. Beneficial effects of lowering blood glucose by using restrictive diet on retinal neurodegeneration in db/db mice. A)
Comparison of TUNEL immunofluorescence (green) between representative samples from a diabetic mouse (db/db) ad libitum (AL) feeding (upper
panel), a db/db mouse under dietary restriction (RD) (middle panel) and a control (db/+) mouse (lower panel) at 10 weeks. B) Percentage of TUNEL
positive cells in the GCL in db/db mice ad libitum feeding (black bars), db/db mice under dietary restriction (gray bars) and control (db/+) mice (white
bars) at 10 weeks. n = 10 each group. *p,0.05 in comparison with db/db feeding AL. **p,0.01 in comparison with db/+. C) Comparison of GFAP
immunoreactivity (green) in the central retina between representative samples from a diabetic mouse (db/db) AL feeding (upper panel), a db/db
mouse under dietary restriction (middle panel) and a control (db/+) mouse (lower panel) at 10 weeks. Nuclei were labeled with Hoechst (blue). ONL:
outer nuclear layer; INL: inner nuclear layer; GCL: ganglion cell layer. D) Quantification of glial activation based on scoring system (see text) (n = 10
each group). E) SOPs implicit time (ms) and F) SOPs amplitude (mV). White bars: before diet intervention. Black bars: after diet intervention. Data are
expressed as mean 6 SD. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0097302.g009
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Figure 10. Comparison of GLAST immunofluorescence between representative samples from non-diabetic and diabetic mice. A)
GLAST immunofluorescence (red) of representative samples from non-diabetic and diabetic mice at 8 weeks, 16 and 24 weeks. Nuclei were labeled
with Hoechts (blue). ONL: outer nuclear layer; INL: inner nuclear layer; GCL: ganglion cell layer. B) Quantification of GLAST immunofluorescence in
non-diabetic (white bars) and diabetic mice (black bars). A.U.: arbitray units. *p,0.05; **p,0.001 between non-diabetic and diabetic mice.
doi:10.1371/journal.pone.0097302.g010
Retinal Neurodegeneration in db/db Mice
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Table 1. Genes up-regulated in retinas of diabetic mice.
ID Symbol Gene name LogFC P Value
71760 Agxt2l1 Alanine-glyoxylate aminotransferase 2-like 1 0.862 2.9E-07
19878 Rock2 Rho-associated, coiled-coil containing protein kinase 2 0.819 1.2E-06
66594 Uqcr11 Ubiquinol-cytochrome c reductase, complex III subunit XI 0.815 4.9E-06
11811 Apobec2 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 0.791 8.0E-08
20341 Selenbp1 Selenium binding protein 1 0.769 1.8E-04
57441 Gmnn Geminin, DNA replication inhibitor 0.706 2.5E-05
15122 Hba-a1 Haemoglobin alpha, adult chain 1/2 0.691 1.4E-03
16668 Krt18 Keratin 18 0.691 9.3E-09
11815 Apod Apolipoprotein D 0.677 5.4E-03
110880 Scn4a Sodium channel, voltage-gated, type IV, alpha subunit 0.599 7.8E-08
19872 Rny1 RNA, Ro-associated Y1 0.591 2.9E-04
20557 Slfn3 Schlafen Family Member 12 0.577 2.4E-05
14719 Got2 Glutamic-oxaloacetic transaminase 2 0.530 2.1E-03
12865 Cox7a1 Cytochrome c oxidase subunit VIIa polypeptide 1 0.511 6.7E-04
56338 Txnip Thioredoxin interacting protein 0.509 6.5E-05
83554 Fstl3 Follistatin-like 3 0.498 1.3E-05
12925 Crip1 Cysteine-rich protein 1 0.496 1.0E-06
319178 Hist1h2bb Histone cluster 1, h2bb 0.486 3.3E-05
11303 Abca1 ATP-binding cassette, sub-family A (ABC1), member 1 0.485 1.7E-06
17873 Gadd45b Growth arrest and DNA-damage-inducible, beta 0.467 8.2E-03
19725 Rfx2 Regulatory factor x,2 0.449 9.6E-04
66929 Asf1b ASF1 anti-silencing function 1 homolog B 0.447 2.4E-05
70893 Glb1l3 Galactosidase, beta 1 like 3 0.441 9.1E-05
11830 Aqp5 Aquaporin 5 0.439 7.1E-03
30794 Pdlim4 PDZ and LIM domain 4 0.437 1.2E-05
19784 Rprl2 Ribonuclease P RNA-like 2 0.427 8.3E-04
75316 Taf1d TATA box binding protein (Tbp)-associated factor, RNA polymerase I, D 0.418 4.5E-05
11927 Atox1 ATX1 (antioxidant protein 1) homolog 1 0.399 3.6E-05
109900 Asl Argininosuccinatelyase 0.397 1.3E-06
108015 Chrnb4 Cholinergic receptor, nicotinic, beta polypeptide 4 0.393 1.5E-03
15561 Htr3a 5-hydroxytryptamine (serotonin) receptor 3A 0.388 6.0E-04
319155 Hist1h4c Histone cluster 1, H4c 0.387 1.1E-03
12306 Anxa2 Annexin A2 0.387 4.3E-04
11854 Rhod Ras homolog gene family, member D 0.386 2.8E-04
18129 Notch2 Notch gene homolog 2 (Drosophila) 0.385 1.6E-05
77462 Tmem116 Transmembrane protein 116 0.380 9.3E-05
70807 Arrdc2 Arrestin domain containing 2 0.378 1.1E-03
11853 Rhoc Ras homolog gene family, member C 0.372 2.9E-05
227292 Ctdsp1 CTD small phosphatase 1 0.372 1.6E-03
171209 Accn3 Amiloride-sensitive cation channel 3 0.371 2.8E-03
69875 Ndufa11 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 11 0.370 3.6E-06
65972 Ifi30 Interferon, gamma-inducible protein 30 0.368 5.5E-04
74760 Rab3il1 RAB3A interacting protein (rabin3)-like 1 0.363 1.2E-04
263406 Plekhg3 Pleckstrin homology domain containing, family G member 3 0.362 6.9E-05
71660 Rarres2 Retinoic acid receptor responder (tazarotene induced) 2 0.355 6.1E-03
212974 Athl1 ATH1, acid trehalase-like 1 0.354 1.2E-03
12036 Bcat2 Branched chain amino-acid transaminase 2 0.354 1.2E-05
68337 Crip2 Cysteine-rich protein 2 0.350 5.4E-03
22228 Ucp2 Uncoupling protein 2 0.349 3.8E-03
66230 Mrps28 Mitochondrial ribosomal protein S28 0.349 1.2E-03
doi:10.1371/journal.pone.0097302.t001
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Nuclear counterstaining with Hoescht stain solution (Sigma-
Aldrich Chemie, Buchs, Switzerland) was performed for micro-
scopic analysis with the laser scanning confocal microscope (TCS
SP2; Leica Microsystems, Wetzlar, Germany). Negative control
was carried out by omitting the primary antibody. Specific labeling
of cleaved caspase-3 antibody in mouse jejunal paraffin sections
was used as positive control.
Transmission electron microscopy analysis. One mm3
retinal fragments were dissected from four 8 week-old db/db mice.
Retinas from four age-matched db/+ mice were used as control
retinas. Retinal fragments were fixed in 2.5% glutaraldehyde and
2% paraformaldehyde, post fixed in 1% osmium tetroxide, stained
in aqueous uranyl acetate, dehydrated and embedded in spurr
resin. Ultrathin sections (70 nm) were stained with lead citrate and
examined under transmission electron microscopy (Jeol 1400; Jeol
Ltd., Tokyo, Japan).
Glutamate Quantification
Quantification of glutamate was performed by liquid-chroma-
tography coupled to mass spectrometry (LC-MS/MS). Chromato-
graphic separation was performed on an Agilent 1200 series
(Waldbronn, Germany) using an Ascentis Express HILIC column,
5062.1 mm with 2.7 Rm particle size from Supelco (Belfonte, PA)
maintained at 25uC throughout the analysis, a mobile phase
acetonitrile and water (50 mM ammonium acetate) with a flow
rate of 0.6 mL min-1. The volume injected was 10 RL. The
mobile phase involved a gradient starting at 87% of ACN which
was maintained for 3 minutes. Then, from min 3 to 10 the ACN
content was decreased to 20% and increased again to 87% at min
12.5. Glutamate was eluted at 6.5 minutes. The mass detection
system was an Agilent 6410 Triple Quad (Santa Clara, CA) using
positive electrospray ionization with a gas temperature of 350uC,
gas flow rate of 12 L min-1, nebulizer pressure of 45 psi, capillary
voltage of 3500 V, fragmentor of 135 V and collision energy of 10
V.
Immunohistochemistry for GLAST
Glutamate/aspartate transporter (GLAST) and L-glutamate
was evaluated by fluorescence microscopy using specific antibod-
ies. Sections were incubated in blocking solution (3% BSA, Tween
0,05% PBS) for 1 h. at room temperature followed by incubation
with primary antibody rabbit anti-GLAST (EAAT1) (1:100,
Abcam ab416, Cambridge, UK). After washing, sections were
incubated with a fluorescent anti-rabbit ALEXA 594 as a
secondary antibody (Life Technologies S.A, Madrid, Spain) in
blocking solution for 1 h, washed, nuclei were stained with
Hoechst and mounted in Mounting Medium Fluorescence
(Prolong, Invitrogen) with a coverslip. Fluorescence intensity of
images was quantified by ImageJ.
DNA Microarrays
Gene expression profiling analysis in retinas of 8-week old
diabetic (db/db) mice and non-diabetic (db/+) controls was
performed using Mouse Gene 1.0 ST DNA arrays (Affymetrix,
UK). For this purpose, total RNA was first isolated from retinas
(n = 4/group) using the RNeasy Mini Kit (Qiagen, Germany) and
200 ng were then used to synthesize sense ssDNA with the
Ambion WT Expression Kit (Life Technologies, UK). Next,
ssDNA was fragmented, labeled and hybridized onto DNA
microarrays using the GeneChip WT Terminal Labeling and
Hybridization Kit and the GeneTitan platform (Affymetrix, UK),
following the manufacturer’s instructions. Microarray Analysis
Suite 5.0 software was used to process the microarray images and
analysis of the data obtained was performed by the Statistics and
Bioinformatics Unit of the Vall d’Hebron-Research Institute using
the open source software Bioconductor.
Gene Expression
Real-time quantitative PCR was used to quantify relative
transcript levels in retinas of 8-week old diabetic and control mice.
400 ng of total RNA were used to synthesize cDNA by using
SuperScript II reverse transcriptase (Life Technologies, USA) and
oligo(dT) primers. Quantitative PCR was performed by using
gene-specific primers and SYBR Green in an ABI PRISM 7500
Sequence Detection System (Applied Biosystems, UK). Relative
mRNA expression was calculated according to the 22DDCT
threshold method, using cyclophilin A as a reference gene [26].
Statistical Analysis
Normal distribution of the variables was evaluated using the
Kolmogorov-Smirnov test. Comparisons of continuous variables
were performed using the paired and unpaired Student t-test.
Levels of statistical significance were set at p,0.05.
Results
Blood Glucose Levels
The diagnosis of diabetes was based on blood glucose levels.
The mice with blood glucose level greater than 250 mg/dl were
confirmed as diabetic mice. In the control group (db/+) blood
glucose levels were ,150 mg/dl during the follow-up whilst all
db/db mice presented blood glucose .250 mg/dl at 4 weeks of
age. Animal body weight and glucose levels are shown in Figure 1.
We observed that hyperglycemia in diabetic mice runs in parallel
with a significant increase of weight.
ERG Abnormalities
The average b-wave implicit times and b-wave amplitudes as a
function of flash intensity are presented in Figure 2 (A–F). The b-
wave implicit time significantly increased in diabetic mice at all
flash intensities tested when compared with non-diabetic mice at
16 and 24 weeks. However, the implicit time was not significantly
delayed in diabetic mice at 8 weeks of age. In addition, b-wave
amplitude was significantly reduced in diabetic mice in compar-
ison with non diabetic mice at 16 and 24 weeks but not at 8 weeks.
The changes observed in amplitude and implicit time of the a-
wave in diabetic mice in comparison with non-diabetic mice were
less marked than that observed in b-wave (Figure 3).
The OPs amplitudes measured under scotopic conditions and
the corresponding implicit times are shown in Figure 2 (G, H). We
detected statistically significant differences (increase of implicit
time and decrease of amplitude) at 16 and 24 weeks.
Retinal Morphometry
Measurements of retinal thickness in diabetic and in non
diabetic mice at 8, 16 and 24 weeks are shown in Figure 2. Since
postnatal growth of retinal thickness exists in C57BL mice until
month 6 [27,28], a progressive increase in the thickness of retinas
from non-diabetic mice was observed whereas this was not the case
in diabetic mice. Total retinal thickness (measured from inner
limiting membrane to Bruch’s membrane) in both central and
peripheral retina was significantly decreased in diabetic mice in
comparison with non-diabetic mice at 16 and 24 weeks (Figure 4).
Furthermore, a thickening in both ONL and INL (Figure 4) as well
as a reduction in the number of cells in the GCL (Figure 5B) was
observed in diabetic mice in comparison with non-diabetic mice at
8, 16 and 24 weeks.
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Table 2. Genes down-regulated in retinas of diabetic mice.
ID Symbol Gene name LogFc P value
12182 Bst1 Bone marrow stromal cell antigen 20.495 9.0E-06
219257 Pcdh20 Protocadherin 20.440 4.0E-04
319554 Idi1 Isopentenyl-diphosphate delta isomerase 1 20.438 6.8E-05
12293 Cacna2d1 Calcium channel, voltage-dependent, alpha 2/delta subunit 1 20.437 4.0E-04
331487 Uprt Uracil phosphoribosyltransferase (FUR1) homolog 20.435 8.6E-04
83924 Gpr137b G protein-coupled receptor 137B 20.407 1.9E-03
66917 Chordc1 Cysteine and histidine-rich domain (CHORD) containing 20.399 3.3E-04
66637 Tsen15 tRNA splicing endonuclease 15 homolog 20.398 7.9E-03
20383 Srsf3 Terine/arginine-rich splicing factor 3 20.390 5.4E-03
26557 Homer2 Homer homolog 2 20.390 1.3E-03
67681 Mrpl18 Mitochondrial ribosomal protein L18 20.383 9.5E-03
217951 Tmem196 Transmembrane protein 20.383 9.9E-04
105727 Slc38a1 Solute carrier family 38, member 1 20.362 4.7E-04
74182 Gpcpd1 Glycerophosphocholine phosphodiesterase GDE1 homolog 20.356 5.7E-06
229279 Hnrnpa3 Heterogeneous nuclear ribonucleoprotein A3 20.352 9.5E-05
21333 Tac1 Tachykinin, precursor 1 20.352 5.2E-03
14405 Gabrg1 Gamma-aminobutyric acid (GABA) A receptor, gamma 1 20.352 4.2E-03
102910 Armcx4 Armadillo repeat containing, X-linked 4 20.351 9.7E-05
59058 Bhlhe22 Basic helix-loop-helix family, member e22 20.351 1.9E-03
14401 Gabrb2 Gamma-aminobutyric acid (GABA) A receptor, beta 2 20.349 5.6E-05
57329 Otor Otoraplin 20.345 1.8E-03
70930 Nol8 Nucleolar protein 8 20.343 3.1E-04
70620 Ube2v2 Ubiquitin-conjugating enzyme E2 variant 2 20.342 9.7E-04
331487 Uprt Uracil phosphoribosyltransferase (FUR1) homolog 20.342 1.2E-03
56353 Rybp RING1 and YY1 binding protein 20.341 9.6E-03
71599 Senp8 SUMO/sentrin specific peptidase family member 8 20.339 8.9E-03
15289 Hmgb1 High mobility group box 1 20.334 6.3E-03
15505 Hsph1 Heat shock 105 kDa/110 kDa protein 20.333 1.1E-03
93739 Gabarapl2 Gamma-aminobutyric acid (GABA) A receptor-associated protein-like 2 20.331 7.1E-03
668923 Zfp442 Zinc finger protein 442 20.328 6.0E-03
72289 Malat1 Metastasis associated lung adenocarcinoma transcript 1 20.325 1.1E-04
14009 Etv1 Ets variant 1 20.325 6.7E-03
11798 Xiap Apoptotic suppressor protein 20.323 2.5E-04
17968 Ncam2 Neural cell adhesion molecule 2 20.320 6.1E-04
76184 Abca6 ATP-binding cassette, sub-family A (ABC1), member 6 20.314 1.4E-03
12300 Cacng2 Calcium channel, voltage-dependent, gamma subunit 2 20.314 4.8E-03
109905 Rap1a RAP1A, member of RAS oncogene family 20.314 8.5E-04
71206 Katnal2 Katanin p60 subunit A-like 2 20.312 4.3E-03
20541 Slc8a1 Solute carrier family 8, member 1 20.312 3.1E-03
14417 Gad2 Glutamate decarboxylase 2 20.311 6.6E-03
14823 Grm8 Glutamate receptor, metabotropic 8 20.310 2.0E-03
14799 Gria1 Glutamate receptor, ionotropic, AMPA 1 20.310 2.8E-04
19128 Pros1 Protein S 20.309 1.1E-03
320772 Mdga2 MAM domain containing glycosylphosphatidylinositol anchor 2 20.307 2.9E-04
243382 Ppm1k Protein phosphatase 1K 20.306 1.5E-03
246229 Bivm Basic, immunoglobulin-like variable motif containing 20.305 8.1E-05
228942 Cbln4 Cerebellin 4 20.304 1.4E-03
11658 Alcam Activated leukocyte cell adhesion molecule 20.303 1.8E-03
18718 Pip4k2a Phosphatidylinositol-5-phosphate 4-kinase, type II, alpha 20.302 2.9E-04
18231 Nxph1 Neurexophilin 1 20.302 8.0E-04
doi:10.1371/journal.pone.0097302.t002
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Neurodegeneration Features
A significant increase in TUNEL-positive inmunofluorescence
was observed in diabetic mice in comparison with retinas from non
diabetic mice at 8, 16 weeks and 24 weeks (Figure 5C). Since the
TUNEL-positive cells were mainly localized in the GCL, we also
counted the percentage of apoptotic cells in this layer, and a
significant increase was found in diabetic mice in comparison with
non-diabetic mice at 8, 16 and 24 weeks (Figure 5D). In addition,
activated caspase-3 was found significantly higher in the retina of
db/db mice in comparison with non-diabetic mice at 8, 16 and 24
weeks (Figure 6).
Since in the ERG measurements we found a-wave abnormal-
ities, which mainly indicate photoreceptor impairment, we wanted
to examine whether apoptosis was also present in photoreceptors.
For this purpose transmision electron microsocopy was used and
striking DNA fragmentation was found in photoreceptors from
db/db mice in comparison with non-diabetic mice (Figure 7).
As expected, in non-diabetic mice GFAP expression was
confined to the retinal GCL (GFAP score #2) (Figure 8). In
contrast, in diabetic mice we observed the ‘‘reactive’’ diabetic
phenotype characterized by upregulation of GFAP in Mu¨ller cells
(GFAP score $2 at week 8 and score = 5 at 16 and 24 weeks).
All these features of neurodegeneration were more intense at 16
than at 8 weeks, but no significant differences between 16 and 24
weeks were observed.
Table 3. Gene enrichment analysis of genes differentially expressed in retinas of diabetic mice.
Ontology GO ID GO Term P value (P,1E-03)
Down-regulated genes
MF GO:0003723 RNA binding 6.18E-08
MF GO:0004971 Alpha-amino-3-hydroxy-5-methyl-4 isoxazole propionate selective glutamate receptor activity1.38E-05
MF GO:0005488 Binding 2.8E-05
MF GO:0022891 Substrate-specific transporter activity 2.1E-04
MF GO:0005313 L-glutamate transporter activity 2.7E-04
MF GO:0046943 Carboxylic acid transporter activity 4.8E-04
BP GO:0007268 Synaptic transmission 2.4E-06
BP GO:0007268 Transmission of nerve impulse 2.98E-06
BP GO:0035637 Multicellular organismal signaling 2.98E-06
BP GO:0015931 Nucleobase-containing compound transport 1.0E-04
BP GO:0044237 Cellular metabolic process 1.0E-04
BP GO:0050657 Nucleic acid transport 1.9E-04
CC GO:0043005 Neuron projection 3.1E-07
CC GO:0045202 Synapse 5.5E-06
CC GO:0005622 Intracellular 5.6E-06
CC GO:0044456 Synapse part 5.9E-06
CC GO:0032279 Asymmetric synapse 2.2E-05
CC GO:0044424 Intracellular part 2.4E-05
Up-regulated genes
MF GO:0003735 Structural constituent of ribosome 8.1E-05
MF GO:0015078 Hydrogen ion transmembrane transporter activity 3.2E-04
MF GO:0004364 Glutathione transferase activity 6.6E-04
MF GO:0019843 rRNA binding 7.7E-04
BP GO:0006979 Response to oxidative stress 6.3E-05
BP GO:0007589 Body fluid secretion 1.4E-04
BP GO:0016049 Cell growth 4.6E-04
BP GO:0034599 Cellular response to oxidative stress 6.3E-04
BP GO:0090208 Positive regulation of triglyceride metabolic process 7.2E-04
BP GO:0070301 Cellular response to hydrogen peroxide 8.5E-04
CC GO:0005840 Ribosome 1.4E-07
CC GO:0070469 Respiratory chain 5.8E-06
CC GO:0022626 Cytosolic ribosome 1.0E-05
CC GO:0044429 Mitochondrial part 1.3E-05
CC GO:0044444 Cytoplasmic part 1.3E-05
CC GO:0005743 Mitochondrial inner membrane 1.4E-05
Only the six most significant gene ontology (GO) terms in each category are shown (MF, molecular function; BP, biological process; CC, cellular compartment).
doi:10.1371/journal.pone.0097302.t003
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Effect of Lowering Blood Glucose on Retinal
Neurodegeneration
As expected, db/db mice fed for 15 days with restrictive diet
presented lower weight and blood glucose levels than those mice
fed with ad libitum diet (weigth: 32.562.8 gr vs. 42.262.5 gr; p,
0.05; blood glucose: 318627 mg/dL vs. 536629 mg/dL, p,
0.01). At this point (after 15 days of dietary restriction) a
significantly lower GFAP immunofluorescence and a lower ratio
of apoptosis in GCL were detected (Figures 9 A–D). Finally, ERG
abnormalities were significantly arrested (Figure 9 E–F).
Markers of Glutamate Pathway
Glutamate levels (mM/g total protein) were higher in diabetic
mice in comparison with non diabetic mice at 8 weeks (6068 vs.
3866; p,0.05), 16 weeks (108612 vs. 56610; p,0.05) and 24
weeks (125611 vs. 5769; p,0.05). The progressive increase of
glutamate levels in diabetic mice run in parallel with a decrease in
GLAST content. GLAST was significantly decreased in diabetic
mice in comparison with the non diabetic mice (Figure 10).
Transcriptomic Analysis
To unravel the molecular mechanisms involved in early retinal
neurodegeneration besides glutamate and its metabolic pathways,
we performed a genome-wide expression profiling analysis on total
RNA isolated from retinas of 8-week old diabetic (db/db) and
control littermate mice. After filtering for redundant and non-
annotated gens, we found that 657 genes were differentially
expressed in retina of diabetic mice (P,0.01). Of these genes, we
found 316 genes to be up-regulated and 341 down-regulated. The
main genes up-regulated and down-regulated are listed in Table 1
and Table 2, respectively. To gain insight into the biological
function of the genes differentially expressed in retinas of diabetic
mice, a gene enrichment analysis was performed. Interestingly, we
found that Gene Ontology (GO) terms significantly enriched
among the down-regulated genes fitted into categories related to
synaptic transmission, with a particular abundance of terms
related to glutamate transport and metabolism (Table 3). On the
other hand, the GO terms significantly over-presented among the
up-regulated genes corresponded to categories related to mito-
chondrial respiration and oxidative stress (Table 3).
Real time quantitative PCR confirmed an aproximately 20%
reduction in the expression of genes related to neurotransmission,
such as inotropic glutamate receptor-1 and -2 (Gria-1 and Gria-2),
metabotropic glutamate receptor 8 (Grm8), glutamine transporter
(Slc38a1) or the subunits b2 and c1 of the gamma-aminobutyric
acid A receptor (Figure 11A). These results suggest that glutamate
signaling and metabolism is altered in diabetic mice.
Interestingly, we have also found that some mitochondrial
genes, most of them encoding for proteins of the respiratory chain,
were mildly increased in retinas of diabetic mice (Figure 11B). A
Figure 11. Relative expression of genes involved neurotransmission (A) and mitochondrial function (B) in retinas of diabetic mice
(black bars) and control non-diabetic mice (white bars) was assessed by real-time quantitative PCR. Results are expressed as mean 6
SEM, n = 9–10/group. *p,0.05.
doi:10.1371/journal.pone.0097302.g011
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parallel increase in the expression of UCP2, a protein involved in
the control of mitochondria-derived reactive oxygen species (ROS)
production, was observed (Figure 11B).
Discussion
Neurodegeneration is an early event and plays a crucial role in
the pathogenesis of DR. In fact, the main features of retinal
neurodegeneration (apoptosis and glial activation) have been
found in the retina of diabetic donors without any microcircula-
tory abnormalities appearing in the ophthalmologic examinations
performed during the year before death [6,29]. In addition, there
are several pieces of evidence to suggest that neurodegeneration
participates in early microvascular abnormalities that occur in DR
[9–11,13,15,30–32]. In this regard, blood-retinal barrier (BRB)
breakdown as the result of VEGF upregulation produced by
glutamate-induced excitotoxicity has been well documented
[9,11,12], and a cross-talk between neurodegeneration and
vasoregression has been reported [10,13]. In addition, the
impairment of neurovascular coupling which can be detected in
diabetic patients without structural abnormalities [32,33] seems
primarily mediated by ganglion cell damage [34]. Finally, it has
been shown that a delayed multifocal ERG implicit time predicts
the development of early microvascular abnormalities [29,35–37].
Therefore, it is reasonable to hypothesize that therapeutic
strategies based on neuroprotection will be effective in preventing
or arresting DR development. However, the morphological and
functional characterization of neurodegeneration in a spontaneous
diabetic model is a challenge that had to be met. In the present
study we have evaluated the neurodegenerative process in retinas
of db/db mice and we have found the same features that occur in
retinas from diabetic donors. These findings permit us to propose
the db/db mouse as a good model for DR and appropriate for
testing neuroprotective drugs.
Mice are more resistant to the STZ effect and present a lower
degree of retinal lesions compared to rats. Nevertheless, because of
its great potential for genetic manipulation, the mouse offers a
unique opportunity to study the molecular pathways involved in
disease development. In the present study we have found that the
spontaneous development of diabetes in db/db mice results in a
progressive thicknness of the neuroretina in comparison with non-
diabetic mice, mainly due to the apoptosis of the ganglion cell
layer (GCL). In this regard, we found a 24% reduction in the
number of cell bodies in the GCL at 8 weeks (after 4 weeks of
hyperglycemia). This reduction increased at 16 weeks to 29%.
These results are in agreement with those recently reported by
Tang et al [22] showing that ganglion cell number and total
retinal thickness are decreased in db/db mice compared with wild-
type controls. In addition, it should be mentioned that, as occurs in
db/db mice, GCL has been the layer with the highest rate of
apoptosis in human retinas [6,7,38]. Noteworthy, thinning of the
GCL has been found in diabetic patients with no or only minimal
DR [6,39–41]. Apart from the loss of cells in the GCL we also
found a thinning of the ONL in db/db mice, which had already
been found at 8 weeks. In this regard we demonstrated DNA
nuclear fragmentation in photoreceptors by using transmision
electron microscopy, thus clearly indicating the presence of
apoptosis. This finding is consistent with the impairment of a-
wave observed in the ERG studies.
Neural apoptosis is accompanied by changes in both types of
glial cells (microglia and macroglia), the most representative being
those occurring in Mu¨ller cells, the predominant type of
macroglial cells. Retinal astrocytes normally express GFAP, while
in Mu¨ller cells this expression is much lower. However, in diabetes
an aberrant overexpression of GFAP is shown by Mu¨ller cells [42].
Cheung et al [19] have previously reported that GFAP and
cleaved caspase 3 labeling were increased in the retina of db/db
mice compared with non-diabetic controls. In the present study we
have found a significant overexpression of GFAP at 8 weeks, thus
running in parallel with the apoptotic changes. This is a significant
feature that has not been found in other spontaneous diabetic mice
such as the Ins2Akita mouse model [43].
In order to explore whether neurodegeneration detected in
homozygous db/db animals is of a genetic nature or related to
hyperglycemia we examined the effect of lowering blood glucose
levels on retinal neurodegeneration. We found a significant
reduction of the most important features of neurodegeneration
(apoptosis, glial activation, ERG abnormalities) by lowering blood
glucose levels in db/db mice. Therefore, diabetes is the main
reason accounting for the retinal neurodegeneration that occurs in
db/db mice.
It is possible that glial activation is a consequence of neural
death. In fact we have recently found the activation of the Fas/
FasL death receptor pathway in the diabetic eye which can induce
the secretion of pro-inflammatory cytokines, thus leading to
neuroinflammation and glial activation [44]. On the other hand,
Mu¨ller cells produce factors capable of modulating blood flow,
vascular permeability, and cell survival. Therefore, these cells
could play a primary role in accounting for neural death. Further
studies to unravel the hierarchical role of apoptosis and glial
activation in the neurodegenerative process of DR are needed.
We have also examined the functional consequences of retinal
neurodegeneration by means of sequential ERG. The abnormal-
ities here reported in db/db mice in b-wave and OPs (reduced
amplitude and prolonged implicit time) were similar to those
described in the early stages of DR in diabetic patients [45,46].
The type of ERG abnormality could help to identify anatomically
the location of retinal damage. In this regard, the OPs have been
shown to be derived from the inner plexiform layers involving the
axon terminals of the bipolar cells, the processes of the amacrine
cells, and the dendrites of the ganglion cells [47]. By contrast,
changes in b-wave amplitudes and implicit times are consistent
with defects in the mid-retinal layer.
Nevertheless, ERG abnormalities in the diabetic retina are not
only due to apoptosis of retinal neurons. In this regard, both glial
activation and changes in blood glucose levels have been involved
in the ERG abnormalities observed in diabetic patients without
cellular loss or major structural damage [48,49].
In the present study we found a progressive increase of
glutamate accumulation in diabetic mice. Glutamate accumula-
tion in extracellular space and the overactivation of glutamate
receptors (‘‘excitotoxicity’’) plays an important role in retinal
neurodegeneration. In fact, elevated levels of glutamate in the
retina have been found in experimental models of diabetes [50–
52], as well as in the vitreous fluid of diabetic patients [53].
Glutamate transporters are essential for keeping the extracellular
glutamate concentration below neurotoxic levels [54]. In this
regard, the glial GLAST, the main glutamate transporter
expressed by Mu¨ller cells, is the most dominant glutamate
transporter, accounting for at least 50% of glutamate uptake in
the mammalian retina [55]. A reduction of GLAST expression in
rat retinas with diabetes induced by STZ has been reported
[56,57]. However, to the best of our knowledge GLAST
expression in db/db mice mouse has not previously been
examined. We observed a significant reduction of GLAST in
diabetic (db/db) mice in comparison with non-diabetic (db/+)
mice. This finding could contribute to the glutamate accumulation
that leads to neurodegeneration in db/db mice. It is worth
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mentioning that we did not find any differences in GLAST mRNA
levels between diabetic and non-diabetic mice, thus suggesting that
the differences in GLAST could be attributed to post-translational
changes.
To the best of our knowledge this is the first transcriptomic
analysis performed in the db/db model. We found a downregu-
lation of several genes related to glutamate metabolism (glutamate
receptors and glutamate transporters) in early stages of DR in db/
db mouse. This finding could lead to the observed extracellular
glutamate accumulation, thus inducing excitotoxicity. As previ-
ously commented, it has been reported that diabetes down-
regulates genes implicated in glutamate transporter in animal
models. However, the information on genes related to glutamate
receptors is controversial and mainly focused in STZ-diabetes
induced animal models [58–61]. Furthermore, we found a
simultaneously upregulation of mitochondrial UCP2 that could
be contemplated as a mechanism to mitigate oxidative stress. This
finding links glutamate excitotoxicity and oxidative stress and
suggests that a vicious cycle involving glutamate excitotoxicithy,
oxidative stress and mitochondrial dynamics reported in a non-
diabetic model of retinal neurodegeneration could also be applied
to diabetic retina [62–65].
In conclusion, the db/db mouse reproduces the features of the
neurodegenerative process that occurs in the human diabetic eye.
Therefore, it seems an appropriate model for investigating the
underlying mechanisms of diabetes-induced retinal neurodegen-
eration and for testing new neuroprotective drugs.
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